Evidence map›Paper›PMID 25085363›Full record

ArticleNeuro-oncology2015

Role of glycosyltransferase PomGnT1 in glioblastoma progression.

Jin Lan, Pin Guo, Yingying Lin, Qing Mao, Liemei Guo, Jianwei Ge, Xiaoxiong Li, Jiyao Jiang, Xinjian Lin, Yongming Qiu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Jin LanDepartment of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.L., P.G., Y.L., Q.M., L.G., J.G., X.X.L., J.J., Y.Q.); The State Key Laboratory of Oncogenes and Related Genes, Shanghai, China (Y.Q.); Department of Medicine and Moores Cancer Center, University of California-San Diego, San Diego, California (X.L.).
Pin GuoDepartment of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.L., P.G., Y.L., Q.M., L.G., J.G., X.X.L., J.J., Y.Q.); The State Key Laboratory of Oncogenes and Related Genes, Shanghai, China (Y.Q.); Department of Medicine and Moores Cancer Center, University of California-San Diego, San Diego, California (X.L.).
Yingying LinDepartment of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.L., P.G., Y.L., Q.M., L.G., J.G., X.X.L., J.J., Y.Q.); The State Key Laboratory of Oncogenes and Related Genes, Shanghai, China (Y.Q.); Department of Medicine and Moores Cancer Center, University of California-San Diego, San Diego, California (X.L.).
Qing MaoDepartment of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.L., P.G., Y.L., Q.M., L.G., J.G., X.X.L., J.J., Y.Q.); The State Key Laboratory of Oncogenes and Related Genes, Shanghai, China (Y.Q.); Department of Medicine and Moores Cancer Center, University of California-San Diego, San Diego, California (X.L.).
Liemei GuoDepartment of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.L., P.G., Y.L., Q.M., L.G., J.G., X.X.L., J.J., Y.Q.); The State Key Laboratory of Oncogenes and Related Genes, Shanghai, China (Y.Q.); Department of Medicine and Moores Cancer Center, University of California-San Diego, San Diego, California (X.L.).
Jianwei GeDepartment of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.L., P.G., Y.L., Q.M., L.G., J.G., X.X.L., J.J., Y.Q.); The State Key Laboratory of Oncogenes and Related Genes, Shanghai, China (Y.Q.); Department of Medicine and Moores Cancer Center, University of California-San Diego, San Diego, California (X.L.).
Xiaoxiong LiDepartment of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.L., P.G., Y.L., Q.M., L.G., J.G., X.X.L., J.J., Y.Q.); The State Key Laboratory of Oncogenes and Related Genes, Shanghai, China (Y.Q.); Department of Medicine and Moores Cancer Center, University of California-San Diego, San Diego, California (X.L.).
Jiyao JiangDepartment of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.L., P.G., Y.L., Q.M., L.G., J.G., X.X.L., J.J., Y.Q.); The State Key Laboratory of Oncogenes and Related Genes, Shanghai, China (Y.Q.); Department of Medicine and Moores Cancer Center, University of California-San Diego, San Diego, California (X.L.).
Xinjian LinDepartment of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.L., P.G., Y.L., Q.M., L.G., J.G., X.X.L., J.J., Y.Q.); The State Key Laboratory of Oncogenes and Related Genes, Shanghai, China (Y.Q.); Department of Medicine and Moores Cancer Center, University of California-San Diego, San Diego, California (X.L.).
Yongming QiuDepartment of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (J.L., P.G., Y.L., Q.M., L.G., J.G., X.X.L., J.J., Y.Q.); The State Key Laboratory of Oncogenes and Related Genes, Shanghai, China (Y.Q.); Department of Medicine and Moores Cancer Center, University of California-San Diego, San Diego, California (X.L.).
Moores Cancer CenterShanghai Jiao Tong University · CNState Key Laboratory of Oncogene and Related Genes · CNUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma multiforme (GBM) is the most aggressive and invasive brain tumor, for which novel prognostic markers and predictors of therapeutic response are urgently needed. We reported previously that levels of peptide-O-linked mannose β-1,2-N-acetylglucosaminyltransferase 1 (PomGnT1) in glioma specimens correlated with tumor grade. However, the prognostic significance of PomGnT1 in glioma patients and its function in GBM progression remain unknown.

methodsClinical relevance of PomGnT1 in GBM patients' prognosis was analyzed both in a clinically annotated expression dataset of 446 GBM tumor specimens and in 82 GBM tumor samples collected at our institution. The function of PomGnT1 in glioma growth and invasion, and the underlying mechanisms of PomGnT1 regulation were explored in vitro and in vivo.

resultsPomGnT1 expression in GBM tissues was closely associated with poor prognosis in GBM patients. Forced overexpression of PomGnT1 in glioblastoma cells impaired cell adhesion and increased their proliferation and invasion in vitro. Subsequent in vivo experiments showed that overexpression of PomGnT1 promoted tumor growth and shortened the survival time of tumor-bearing mice in an orthotopic model. Conversely, stable short hairpin RNA-mediated knockdown of PomGnT1 expression produced opposite effects both in vitro and in vivo. Mechanistic studies revealed that activation of epidermal growth factor receptor (EGFR) resulted in EGFR/extracellular signal-regulated kinase-dependent upregulation of PomGnT1, downregulation of receptor-type protein tyrosine phosphatase β, and activation of β-catenin pathway signaling.

conclusionThese findings suggest that PomGnT1 promotes GBM progression via activation of β-catenin and may serve as a prognostic factor for glioma patient survival as well as a novel molecular target for anticancer therapy in malignant glioma.

Indexed as

Disease ProgressionAdultAgedAged, 80 and overAnimalsbeta CateninBrain NeoplasmsCell Line, TumorCell ProliferationErbB ReceptorsFemaleGlioblastomaHumansMaleMAP Kinase Signaling SystemMicebeta CateninErbB ReceptorsN-Acetylglucosaminyltransferasesprotein O-mannose beta-1,2-N-acetylglucosaminyltransferaseReceptor-Like Protein Tyrosine Phosphatases, Class 5glioblastomaPomGnT1prognosisprogression

Identifiers

PMID25085363
PMCPMC4288519
OpenAlexW2125499128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.